Compare BBAI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBAI | SNDX |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2014 |
| Metric | BBAI | SNDX |
|---|---|---|
| Price | $3.82 | $23.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $5.50 | ★ $84.17 |
| AVG Volume (30 Days) | ★ 33.3M | 1.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $31.26 | $112.05 |
| Revenue Next Year | N/A | $51.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $2.36 | $8.59 |
| 52 Week High | $9.39 | $25.16 |
| Indicator | BBAI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 62.04 |
| Support Level | $3.66 | $19.46 |
| Resistance Level | $4.52 | $25.16 |
| Average True Range (ATR) | 0.25 | 1.24 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 16.89 | 74.79 |
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.